Navigation Links
Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma
Date:9/27/2007

First twice-daily leukotriene synthesis inhibitor provides additional

treatment option for asthma patients not fully controlled on other

medications

NAPA, Calif., Sept. 27 /PRNewswire-FirstCall/ -- Dey, L.P., an affiliate of Merck KGaA of Darmstadt, Germany, announced today that it has launched ZYFLO CR(TM) (zileuton) extended-release tablets with its marketing partner, Critical Therapeutics, Inc. (Nasdaq: CRTX). ZYFLO CR(TM) offers twice-daily, extended-release dosing for the prevention and chronic treatment of asthma in patients 12 years of age and older.

"We are excited to partner with Critical Therapeutics to bring a twice-daily formulation of ZYFLO(R) (zileuton tablets) to the many patients affected by chronic asthma," said Christy Taylor, Executive Vice President, Sales, Marketing and Business Development at DEY. "Our collaboration with Critical Therapeutics and the launch of ZYFLO CR(TM) demonstrate our commitment to developing and marketing innovative respiratory therapeutics to enhance patients' lives."

In March 2007, Critical Therapeutics and DEY entered into an agreement for the co-promotion of ZYFLO CR(TM) and ZYFLO(R), the immediate-release formulation of zileuton. DEY's sales force began promoting ZYFLO(R) on April 30, 2007. ZYFLO CR(TM) received approval from the U.S. Food and Drug Administration on May 31, 2007.

About ZYFLO CR and ZYFLO

ZYFLO CR(TM) and ZYFLO(R) (zileuton tablets) are the only FDA-approved leukotriene synthesis inhibitors for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older. ZYFLO CR(TM) and ZYFLO(R) are not indicated for use in the reversal of bronchospasm in acute asthma attacks, but can be continued during acute exacerbations of asthma. Leukotrienes are inflammatory mediators in asthma that can trigger asthma symptoms, including inflammation, swelling, bronchoconstriction and mucus secretion. ZYFLO CR(TM) uses SkyePharma PLC's (LSE: SKP) proprietary Geomatrix(R) drug delivery technology, which controls the amount and rate of drug released into the body.

The recommended dose of ZYFLO CR(TM) is two 600 mg extended-release tablets twice daily, within one hour after morning and evening meals, for a total daily dose of 2400 mg. The recommended dose of ZYFLO(R) is one 600 mg immediate-release tablet four times a day for a total daily dose of 2400 mg.

ZYFLO CR(TM) and ZYFLO(R) are contraindicated in patients with active liver disease or transaminase elevations greater than or equal to three times the upper limit of normal. A small percentage of patients treated with ZYFLO CR(TM) (2.5%) and ZYFLO(R) (1.9%) in placebo-controlled trials showed an increased release of a liver enzyme known as ALT and bilirubin (an orange or yellowish pigment in bile). As a result, the level of liver enzymes in patients treated with ZYFLO CR(TM) and ZYFLO(R) should be measured by a simple blood test. It is recommended that physicians perform this test before administering ZYFLO CR(TM) and ZYFLO(R) and repeat the test on a regular basis while patients are on the medication. Patients taking ZYFLO CR(TM) and theophylline should reduce the theophylline dose by 50%. Patients taking ZYFLO CR(TM) and propranolol or warfarin should be monitored and doses adjusted as appropriate. Most common side effects associated with the use of ZYFLO CR(TM) and ZYFLO(R) are sinusitis, nausea and pharyngolaryngeal pain and abdominal pain, upset stomach and nausea, respectively.

For full prescribing information for ZYFLO CR(TM), please visit http://www.zyflocr.com or call the Company's toll free telephone number 1-866-835-8216 to request medical information.

For full prescribing information for ZYFLO(R), please visit http://www.zyflo.com or call the Company's toll free telephone number 1-866-835-8216 to request medical information.

About Dey, L.P.

Dey, L.P. is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, respiratory-related allergies, and emergency care medicine. As the US leader in nebulized respiratory medication, DEY puts patients first through its development of innovative and affordable therapies. The Web sites for DEY include http://www.dey.com, http://www.accuneb.com, http://www.curosurfusa.com, http://www.cyanokit.com, http://www.duoneb.com, http://www.epipen.com and http://www.perforomist.com. Dey, L.P. is an affiliate of Merck KGaA, Darmstadt, Germany.

ZYFLO is a registered trademark of Critical Therapeutics, Inc.

ZYFLO CR is a trademark of Critical Therapeutics, Inc.

GEOMATRIX is a registered trademark of SkyePharma PLC.

Media contacts: Dey, L.P. Media Line

1-800-755-5560 ext. 8363

or

Harriet Ullman

Feinstein Kean Healthcare

617-761-6776

hullman@fkhealth.com


'/>"/>
SOURCE Dey, L.P.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Critical factors for successful microarray and real-time PCR analyses
2. MicroRNA Profiling by Array Analysis Reveals Critical BioMarkers
3. Chicago-Milwaukee "mega-metro" infrastructure improvements are critical
4. Caden Biosciences may signal critical mass
5. IT critical in pandemic response, but many are not paying attention
6. IT is critical for economic growth, says UW business dean
7. JohnLets Get Serious - Manufacturing is a critical part of the Wisconsin economy
8. Diamond Film May Enable Critical New Sensors For Bioterror
9. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
10. Merge launches diagnostic mammography workstation in Europe
11. Einstein Wireless launches cellular alert system
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... 07, 2016 , ... ACEA Biosciences, Inc. presented today updated ... trial for its lead drug candidate, AC0010, at the World Conference on Lung ... determine the safety, antitumor activity, and recommended phase II dosage of AC0010 in ...
(Date:12/7/2016)... ... December 07, 2016 , ... Huffman Engineering, Inc. , ... Wonderware Certified System Integrator Partner. Huffman Engineering is the only Nebraska-based company ... System Integrator Partner certification gives customers confidence that our engineers are fully trained ...
(Date:12/7/2016)... 2016 /PRNewswire/ - OncoQuest Inc. ("OncoQuest"), a biopharmaceutical ... immunotherapeutic products for the treatment of cancer, today ... Manufacturing Development Program with Cytovance Biologics ( ... oregovomab antibody product. Supported by recent positive interim ... in ovarian cancer patients, OncoQuest has engaged Cytovance ...
(Date:12/7/2016)... 2016  Nordion, a standalone business of Sterigenics ... today,s award by the United States Department of ... the Phase II cooperative agreement funding to GA ... University of Missouri Research Reactor Center (MURR ® ... establishment of a new, reliable supply of molybdenum ...
Breaking Biology Technology:
(Date:11/30/2016)... Nov. 30, 2016 Not many of us realize that we spend ? ... so we need to do it well. Inadequate sleep levels have been found to ... stroke, diabetes, and even cancer. Maybe now is the best time to ... help them to manage their sleep quality? Continue Reading ... ...
(Date:11/28/2016)... 2016 "The biometric system ... The biometric system market is in the growth ... near future. The biometric system market is expected to ... a CAGR of 16.79% between 2016 and 2022. Government ... technology in smartphones, rising use of biometric technology in ...
(Date:11/19/2016)... Securus Technologies, a leading provider of civil ... corrections and monitoring, announced today that it has offered ... an independent technology judge determine who has the largest ... telephone calling platform, and the best customer service. ... of what we do – which clearly is not ...
Breaking Biology News(10 mins):